Top 100 Agencies: MedThink Communications

Share this article:
Website and social media work for Salix Pharmaceuticals
Website and social media work for Salix Pharmaceuticals

MedThink Communications experienced a year of flux in 2011, with co-founder Walt Clarke stepping out of the firm's day-to-day-operations, leaving president Scott Goudy to run the show under “a singular vision.” The Raleigh-based agency ended the year basically flat, Goudy said last year.

Things were significantly better in 2012, however. MedThink grew 15%, picking up a couple of new clients, and beefed up its creative and digital offering with new hires.

“It turned out to be a good year,” says Goudy. “We experienced nice growth overall and did some things  that positioned us for the future.”

A lot of that setting up for the future involved staff changes and additions. One major change was the hire of new creative leader Joe Marcoux from inVentiv's Ignite Health. Marcoux, who took on the role of group creative director, has deep Big Pharma and consumer brand experience. His resume includes companies from Bristol-Myers Squibb and GSK to Absolut Vodka, Citibank and Microsoft.

MedThink's positioning leans hard on integration, with core areas being advertising and promotion, digital services, and media planning and analytics. “Development,” Goudy says, “is an important part of the product” and, thus, most of it is done in house.

MedThink gained a new digital leader in Brian Sobus, the agency's director of technology. Goudy noted that 30-40% of the typical brand's budget is digital and that MedThink's proportion of digital skews higher than that. He noted that MedThink is seeing growth across the major digital areas.

“Websites are still important but we're seeing more mobile, more social,” Goudy said. “Social media is an area where pharmas have been hesitant and continues to be. Some are starting to figure it out and dip toes into the water deeper. They're also getting better at utilizing analytics to understand effectiveness.”

While digital is increasingly important to agencies of all stripes, Goudy says that MedThink's revamped creative department still has a combination of traditional and interactive capabilities. “It's imperative that [our creatives] have digital expertise and are also able to handle traditional media,” he notes. “But we do err on the side of having digital expertise.”

In 2012, MedThink's headcount grew from 60 to about 70. (Hires early this year put the current staff at about 75.) Goudy's projected growth for 2013 is a heady 30%. But there appears to be an inverse relationship between that growth and how much Goudy is willing to talk about.

Asked to name the “couple of new clients” MedThink has added, Goudy declined. “With all our clients now there's contractual obligations not to disclose the information.” (In the past, MedThink has identified Salix, Glenveigh Medical, Rho, United Therapeutics, Teva Neuroscience and Wilmington Pharmaceuticals as clients of the firm.)

As for creative highlights, such as MedThink's well-regarded Colonoscopy for Dummies programs, Goudy was once again circumspect, saying,  “Our clients don't want that disclosed.”

He also said that there were no major client losses for the agency: “We chose not to do business with a couple of small accounts that weren't productive.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?